Indivior PLC (INDV)
| Market Cap | 4.12B +165.9% |
| Revenue (ttm) | 1.18B -0.2% |
| Net Income | 124.00M |
| EPS | 0.98 |
| Shares Out | 124.85M |
| PE Ratio | 33.60 |
| Forward PE | 11.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,112,565 |
| Open | 33.70 |
| Previous Close | 33.54 |
| Day's Range | 32.82 - 33.84 |
| 52-Week Range | 7.62 - 38.00 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 35.75 (+8.43%) |
| Earnings Date | Feb 19, 2026 |
About INDV
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price target is $35.75, which is an increase of 8.43% from the latest price.
News
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convert...
Indivior Announces Proposed Convertible Senior Notes Offering
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate p...
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergenc...
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, and pr...
Indivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th An...
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, ...
Indivior Announces Completion of Redomiciliation to the United States
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE ® Net Revenue Expected to be in the Range of $905 million to $945 million Non-GAAP Operating Expenses Expec...
Indivior Announces Inclusion in the S&P SmallCap 600® Index
RICHMOND, Va. , Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today.
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance ...
Indivior Concludes Legacy U.S. Department of Justice Matter
RICHMOND, Va. , Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding...
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Hea...
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lowe...
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Indivior PLC ( INDV) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Jason Thompson - Vice President of Investor Relations Joseph Ciaffoni - CEO & Director Patrick Barry - Chi...
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY Announces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support o...
Indivior to Participate in the Stifel 2025 Healthcare Conference
RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference: Stifel 2025 Healthcare Conference – New Yor...
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m.
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants RICHMOND, Va. , Oct. 15, 2025 /PRNewswire/ -- ...
UK's Indivior to re-domicile to US after listing move
Indivior , said on Wednesday it plans to relocate its corporate domicile from the UK to the United States, establishing a new Delaware-based parent company, just months after the pharmaceutical firm m...
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
RICHMOND, Va. , Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and ...
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Indivior PLC (NASDAQ:INDV) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Joseph Ciaffoni - CEO & Director Ryan Preblick - Chief Financial ...
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events: Morgan Stanley 23rd Annual Global Healthcare Confer...
Indivior's Strategic Turnaround Gains Traction Post-Q2 2025
Indivior's turnaround is driven by SUBLOCADE's strong growth, improved cash flow, and a three-phase recovery plan that the market undervalues. Q2 2025 results beat expectations, with SUBLOCADE deliver...
Indivior PLC (INDV) Q2 2025 Earnings Call Transcript
Indivior PLC (NASDAQ:INDV) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Joseph J. Ciaffoni - CEO & Director Pat...